Perioperative management of patients with rheumatic disorders: problems and solutions

Currently management of patients with rheumatic disorders (RD) involves not only application of all of the known spectrum of mediations in accordance with current guidelines and algorithms but also timely use of high-tech medical care, for example, endoprosthesis of the large joints, spinal surgery, dental care, endovascular surgery, aimed at decreasing the level of disability and improving patients’ quality of life. The article considers modern approaches to management of patients with RD in the perioperative period, special emphasis is given to administration of background anti-inflammatory and genetically engineered biological medications, as well as prevention of thrombosis of the deep veins and thromboembolic complications. In the postoperative period, use of pharmacological control of development of “painful endoprosthesis” is vital as it is the main cause of unsatisfaction with the outcome of orthopedic aid. An effective method for controlling pain syndrome in patients with RD is use of non-steroidal anti-inflammatory drugs (NSAIDs). Selection of a specific NSAID should be based on the knowledge of gastrointestinal and cardiovascular side effects, as well as evidence of effectiveness in the perioperative period. In the group of patients with RD, namely with ankylosing spondylitis and psoriatic arthritis, prevention of heterotopic ossification after orthopedic manipulations, endoprosthesis is very important. Considering high comorbidity in RD, it is necessary to determine perioperative risk taking into account patient’s condition and operative urgency: to evaluate clinical features of the main and concomitant disorder (ischemic heart disease, cerebrovascular pathology, diabetes mellitus, chronic kidney disease), type of the surgery, results of electrocardiogram at rest, lab tests, and other noninvasive procedures. Correct planning of management of the perioperative period in patients with RD, adequate pain relief prior to surgery and after it, early activization are the main elements of rehabilitation of patients with pathologies of the locomotor apparatus.

1. Balabanova R.M., Dubinina T.V., Demina A.B., Krichevskaya O.A. Incidence of diseases of the musculoskeletal system in the Russian Federation in 2015– 2016. Nauchno-practicheskaya revmatologiya = Scientific and Practical Rheumatology 2018;56(1):15–21. (In Russ.)

2. Smolen J.S., Landewè R., Bijlsma J. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76(6):960–77. DOI:10.1136/annrheumdis-2016-210715.

3. Bruyèr O., Cooper C., Pelletier J.P. et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum 2014;44(3):253–63. DOI:10.1016/j.semarthrit.2014.05.014.

4. Gossec L., Smolen J.S., Ramiro S. et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016;75(3):499–510. DOI: 10.1136/annrheumdis-2015-208337.

5. Doran M.F., Crowson C.S., Pond G.R. et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002;46(9):2294–300. DOI:10.1002/art.10529.

6. Schrama J.C., Espehaug B., Hallan G. et al. Risk of revision for infection in primary total hip and knee arthroplasty in patients with rheumatoid arthritis compared with osteoarthritis: a prospective, population-based study on 108,786 hip and knee joint arthroplasties from the Norwegian Arthroplast Register. Arthritis Care Res 2010;62(4):473–9. DOI: 10.1002/acr.20036.

7. Smitten A.L., Choi H.K., Hochberg M.C. et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 2008;35(3):387–93.

8. Amirjanova V.N. Perioperative management of patients with rheumatoid arthritis requiring endoprosthesis of the large joints of the lower extremities. The Association of Rheumatologists of Russia. Available at: https://diseases.medelement.com/disease/периоперационное-ведение-пациентов-с-ревматоидным-артритом-нуждающихся-в-эндопротезировании-крупных-суставов-ниж-них-конечностей-рекомендации-рф/15103. (In Russ.)

9. Goodman S.M., Springer B., Guyatt G. et al. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis Rheumatol 2017;69(8):1538–51. DOI:10.1002/art.40149.

10. Grennan D.M., Gray J., Loudon J. Fear S. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis 2001;60:214–7. DOI:10.1136/ard.60.3.214.

11. Tanaka N., Sakahashi H., Sato E. et al. Examination of the risk of continuous leflunomide treatment on the incidence of infectious complications after joint arthroplasty in patients with rheumatoid arthritis. J Clin Rheumatol 2003;9:115–8. DOI:10.1097/01.RHU.0000062514.54375.bd.

12. Goodman S.M., Friedlander R., Figgie C. et al. Flares occur frequently in RA patients undergoing arthroplasty. Arthritis Rheumatol 2015;67. Abstr. 2664.

13. Strand V., Ahadieh S., French J. et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying anti-rheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther 2015;17:362. DOI:10.1186/s13075-015-0880-2.

14. Singh J.A., Cameron C., Noorbaloochi S. et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and metaanalysis. Lancet 2015;386:258–65. DOI:10.1016/S0140-6736(14)61704-9.

15. Tarp S., Tarp U., Andersen L.S. et al. Serious adverse events associated with using biological agents to treat rheumatic diseases: network meta-analysis from a national guideline panel [abstract]. Arthritis Rheum 2013;65(10 Suppl):997–8.

16. Furie R., Petri M., Zamani O. et al. A phase III, randomized, placebocontrolled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918–30. DOI:10.1002/art.30613.

17. Ginzler E.M., Wallace D.J., Merrill J.T. et al. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol 2014;41: 300–9. DOI:10.3899/jrheum.121368.

18. Recommendations ESC/ESA for preoperative examination and patient management in performing non-cardiac surgical interventions 2014. Rossijskij kardiologicheskij zhurnal = Russian Journal of Cardiology 2015;8(124):7–66. (In Russ.)

19. Glance L.G., Lustik S.J., Hannan E.L. et al. The Surgical Mortality Probability Model: derivation and validation of a simple risk prediction rule for noncardiac surgery. Ann Surg 2012; 255:696–702. DOI:10.1097/SLA.0b013e31824b45af.

20. Howe C.R., Gardner G.C., Kadel N.J. Perioperative medication management for the patient with rheumatoid arthritis. J Am Acad Orthop Surg 2006;14(9):544–51. DOI:10.5435/00124635-200609000-00004.

21. Leese P.T., Hubbard R.C., Karim A. et al. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 2000;40(2):124–32. DOI:10.1177/00912700022008766.

22. Oscarsson A., Gupta A., Fredrikson M. et al. To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. Br J Anaesth 2010;104(3):305–12. DOI:10.1093/bja/aeq003.

23. Möllmann H., Nef H.M., Hamm C.W. Clinical pharmacology: antiplatelet therapy during surgery. Heart 2010;96(12):986–91. DOI:10.1136/hrt.2008.155655.

24. Slappendel R., Weber E.W., Benraad B. et al. Does ibuprofen increase perioperative blood loss during hip arthroplasty? Eur J Anaesthesiol 2002;19(11):829–31. DOI:10.1017/S0265021502001345.

25. Russian clinical guidelines for the diagnosis, treatment and prevention of venous thromboembolic complications (VTEC). Flebologiya = Phlebology 2015;4(2):1–52. (In Russ.)

26. Bourne R., Chesworth B., Davis A. et al. Patient Satisfaction after Total Knee Arthroplasty. Who is Satisfied and Who is Not? Clin Orthop Relat Res 2010;468:57–63. DOI:10.1007/S11999-009-1119-9.

27. Wylde V., Hewlett S., Learmonth I., Dieppe P. Persistent pain after joint replacement: prevalence, sensory qualities, and postoperative determinants. Pain 2011;152(3):566–72. DOI:10.1016/J.PAIN.2010.11.023.

28. Liu S.S., Buvanendran A., Rathmell J.P. et al. A cross-sectional survey on prevalence and risk factors for persistent postsurgical pain 1 year after total hip and knee replacement. Reg Anesth Pain Med 2012;37(4):415–22. DOI:10.1097/AAP.0B013E318251B688.

29. Piscitelli P., Iolascon G., Innocenti M. et al. Painful prosthesis: approaching the patient with persistent pain following total hip and knee arthroplasty. Clin Cases Miner Bone Metab 2013;10(2):97–110.

30. Hofmann S., Seitlinger G., Djahani O., Pietsch M. The painful knee after TKA: a diagnostic algorithm for failure analysis. Knee Surg Sports Traumatol Arthrosc 2011;19(9):1442–52. DOI:10.1007/s00167-011-1634-6.

31. Kienapfel H., Koller M., Wüst A. et al. Prevention of heterotopic bone formation after total hip arthroplasty: a prospective randomised study comparing postoperative radiation therapy with indomethacin medication. Arch Orthop Trauma Surg 1999;119(5–6):296–302. DOI:10.1007/s004020050414.

32. Iorio R., Healy W.L. Heterotopic ossification after hip and knee arthroplasty: risk factors, prevention, and treatment. J Am Acad Orthop Surg 2002;10(6):409–16. DOI:10.5435/00124635-200211000-00005.

33. Asghar W., Jamali F. The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Inflammopharmacology 2015;23(1):1–16. DOI:10.1007/s10787-014-0225-9.

34. Akarsu T., Karaman S., Akercan F. et al. Preemptive meloxicam for postoperative pain relief after abdominal hysterectomy. Clin Exp Obstet Gynecol 2004;31(2):133–6.

35. Weber E.W., Slappendel R., Durieux M.E. et al. COX 2 selectivity of non-steroidal anti-inflammatory drugs and perioperative blood loss in hip surgery. A randomized comparison of indomethacin and meloxicam. Eur J Anaesthesiol 2003;20(12):963–6.